Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager

Vir Biotechnology, Inc.

Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
Eligible for up to $1.37 billion in development, regulatory and sales milestones plus tiered double-digit royalties on ex-U.S. net sales.
Global development costs shared 40% Vir Bio / 60% Astellas; U.S. profits/losses split 50/50 with Vir co-promotion option.
Phase 1 data for VIR-5500 shows dose-dependent anti-tumor activity; oral presentation at ASCO GU 2026 on February 26.
Cash and investments $781.6M as of Dec 31, 2025; net loss for full year 2025 was $438.0 million.

item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Vir Biotechnology, Inc. issued 7,239,382 shares of common stock to Astellas for an aggregate purchase price of approximately $75 million.

Security: common stock
Shares: 7,239,382 shares
Purchaser: Astellas
Consideration: an aggregate purchase price of approximately $75 million

Exact text from the filing

Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. entered into Collaboration and License Agreement with Astellas US LLC valued at $335 million in upfront and near-term milestone payments (effective 2026-02-19).

Action: entry
Agreement: collaboration
Counterparty: Astellas US LLC
Value: $335 million in upfront and near-term milestone payments
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, Vir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vir Biotechnology, Inc. entered into Stock Purchase Agreement with Astellas US LLC valued at approximately $75 million (effective 2026-02-19).

Action: entry
Agreement: equity purchase
Counterparty: Astellas US LLC
Value: approximately $75 million
Effective: 2026-02-19

Exact text from the filing

Concurrently with the execution of the Agreement, Vir Bio also entered into the SPA, pursuant to which Astellas has agreed to purchase 7,239,382 shares of Vir Bio’s common stock, par value $0.0001 per share (Common Stock), for an aggregate purchase price of approximately $75 million, subject to customary closing conditions.

View on SEC.gov

Browse all equity issuances →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-010740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.